Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865190 | 1.00 | TP53 (0.40) | TP53SLC7A5 | |
| SCHEMBL11996286 | 1.00 | TP53 (0.40) | TP53SLC7A5 | |
| Hydrochloric Acid SCHEMBL28540309 | 0.97 | TP53 (0.38) | TP53SLC7A5 | |
| SCHEMBL22692567 | 0.88 | TP53 (0.44) | TP53SLC7A5 | |
| SCHEMBL718215 | 0.88 | TP53 (0.44) | TP53SLC7A5 | |
| Sulfuric Acid SCHEMBL28413874 | 0.78 | TP53 (0.38) | TP53 | |
| SCHEMBL13033877 | 0.77 | TSHR (0.35) | — | |
| SCHEMBL25847798 | 0.76 | TDP1 (0.30) | — | |
| SCHEMBL22692558 | 0.76 | RNPEP (0.36) | TP53 | |
| SCHEMBL50988 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220298138-A1 | ENZYME INHIBITORS | SYGNATURE DISCOVERY LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4017586-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114269431-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3804725-A2 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | Rhode Island Hospital (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032933-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| US-20190350960-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-11-21 | — | — | US | disclosed |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DeCODE Genetics enf (IS) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051673-A1 | AMINOTHIAZOLE DERIVATIVES USEFUL AS KLK1 INHIBITORS | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051672-A1 | AZAINDOLE DERIVATIVES | VANTIA LIMITED (GB) | 2011-05-05 | — | — | WO | disclosed |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-03-29 | — | — | US | disclosed |
| US-6489498-B2 | REDUCE SURFACE TENSION; BIODEGRADATION | TH. GOLDSCHMIDT AG (DE) | 2002-12-03 | — | — | US | disclosed |
| US-20010018535-A1 | Silanes with hydrophilic groups, their synthesis and use as surfactants in aqueous media | GOLDSCHMIDT GMBH (DE) | 2001-08-30 | — | — | US | disclosed |
| US-6255511-B1 | RESISTANT TO HYDROLYSIS IN ACIDIC AND ALKALINE MEDIA | TH GOLDSCHMIDT AG (DE) | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018535-A1 | Silanes with hydrophilic groups, their synthesis and use as surfactants in aqueous media | SGMS1, SSR4, SULT1A1 | TP53 1374/4885SLC7A5 122/4885 |
| US-20090136473-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | TP53 3957/4885SLC7A5 4749/4885 |
| US-20220298138-A1 | ENZYME INHIBITORS | SERPINB1, CMA1, MAOB | TP53 2070/4885SLC7A5 3878/4885 |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | TP53 2829/4885SLC7A5 4036/4885 |
| US-20070072934-A1 | Alkoxy indolinone based protein kinase inhibitors | PHKG1, MAP3K19, MAP3K20 | TP53 698/4885SLC7A5 2445/4885 |
| US-20120213758-A1 | BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS | PDE4A, PDE4B, PDE3B | TP53 3957/4885SLC7A5 4749/4885 |
| US-20190350960-A1 | MODULATING NUDIX HOMOLOGY DOMAIN (NHD) WITH NICOTINAMIDE MONONUCLEOTIDE ANALOGS AND DERIVATIVES OF SAME | NAMPT, NME4, NUDT15 | TP53 610/4885SLC7A5 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.